

1

2 **Optimisation of a Novel Glass-Alginate Hydrogel for the Treatment of Intracranial Aneurysms**

3

S.A. Brady^a, E.K. Fox^a, C. Lally^b, O.M. Clarkin^a

4

^aSchool of Mechanical & Manufacturing Engineering, Dublin City University, Dublin 9, Ireland

5

^bMechanical & Manufacturing Engineering, Trinity College Dublin, Dublin 2, Ireland

6

Corresponding author

7

Email address: owen.clarkin@dcu.ie

8

Tel.: +353 1 7006496

9

Present address: School of Mechanical & Manufacturing Engineering, Dublin City University, Dublin 9,

10

Ireland

11

Other authors

12

Email address: sarah.brady33@mail.dcu.ie

13

lallyca@tcd.ie

14

eoin.fox5@mail.dcu.ie

15

Abstract

16

The current gold standard for aneurysm treatment is endovascular coiling. However, recurrence is observed in over 20% of cases. A novel hydrogel has been developed to treat aneurysms. This hydrogel is composed of a polymeric alginate, a novel ion releasing glass and glucono-delta-lactone. This is an internally setting alginate hydrogel, wherein the setting rate can be controlled by both the glass and the alginate chemistry. The aim of this work is to examine the effect of each component of the hydrogel and optimise the composition of the hydrogel, specifically the alginate molecular weight, M/G ratio and concentration. The effects of gamma sterilisation will also be examined. The results show that alginate concentration, chemical composition and molecular weight affect the compressive strength, working time, hardening time and deliverability of the hydrogel. Gamma irradiation of the alginate reduces the molecular weight, which has a negative effect on the usability of this hydrogel.

26

27

Keywords

28

Alginate, molecular weight, chemical composition, concentration, hydrogel, intracranial aneurysm

29

1. Introduction

An intracranial aneurysm is an irregular out-pouching of a cerebral artery. It is estimated that 1% to 6% of the adult population has an intracranial aneurysm (Brisman, Song, & Newell, 2006). A ruptured aneurysm can lead to stroke, resulting in disability or death. Treatments such as clipping and coiling are currently used to prevent an aneurysm from rupturing; however, there are a number of problems associated with these. Clipping the aneurysm involves a craniotomy and carries the risks of infection and scarring (Brisman et al., 2006). In the United States, the most common treatment method for intracranial aneurysms is coiling. However, recurrence is common, happening in 20.8% of endovascular coiling cases (Crobeddu, Lanzino, Kallmes, & Cloft, 2012), indicating that it is a suboptimal treatment method.

In this study we explore the possibility of delivering a hydrogel which will fill the aneurysm more completely and prevent rupture. This novel hydrogel composite is composed of a polymeric alginate, a novel ion releasing glass and glucono-delta-lactone (GDL).

Ideally, the hydrogel should adhere to the aneurysm wall preventing migration and aneurysm recurrence. Additionally, the hydrogel must be able to withstand a compressive stress of at least 22kPa, which relates to hypertensive blood pressure (Cipolla MJ, 2009). The envisaged hydrogel delivery procedure will involve inflating a compliant balloon adjacent to the aneurysm neck, as with endovascular coiling. The novel hydrogel will then be injected through a micro-catheter into the aneurysm whilst the inflated balloon prevents leakage of the filler into the blood stream (see Figure S 1). To allow for delivery, an optimum working time of between 10 and 30 minutes has been determined by clinical observation. It has been determined that the novel hydrogel must be set within 5 minutes of injection (based on the maximum inflation time for a balloon in the cerebral vasculature. A balloon inflated for greater than 5 minutes may result in cerebral ischemia (Kim Nelson & Levy, 2001). The alginate sterility must also be considered and this can ordinarily be achieved by moist heat sterilization, gamma-irradiation or ethylene oxide sterilization (Munarin, Bozzini, Visai, Tanzi, & Petrini, 2013).

Alginate is a polysaccharide composed of β -D-mannuronic acid (M) and α -L-guluronic acid (G), giving alginate an M/G block structure. Alginate has the ability to gel when cross-linked with multivalent ions. Alginate is typically described in terms of molecular weight and the M/G ratio. G-rich alginates are stiffer and more brittle than M-rich alginates (Morais et al., 2013).

The role of the glass in this hydrogel is to deliver a steady release of multivalent ions, controlling the rate of gelation and the strength of the hydrogel. The more stable the glass the slower the rate of gelation. A glass that releases a higher quantity of ions will form a stronger hydrogel. Bioactive glasses have also traditionally been used to deliver therapeutic ions, which encourage cell growth and extracellular matrix production. This hydrogel formulation could also, in the future, be used to deliver therapeutic ion doses.

63 GDL is a lactone that hydrolyses in water to form a gluconic acid, its role in the novel hydrogel is to
64 acidify the solution. This in turn releases multivalent ions, contained in the glass, allowing them to cross-
65 link with the alginate. The gelation rate of the hydrogel can be tightly controlled by both the composition
66 of the glass phase and the ratio of constituent components of the gel. An increased amount of GDL results
67 in increased acidity, causing a more rapid glass ion release and a more rapid gelation.

68 The aim of this work is to individually vary the concentration of two different alginates, with similar
69 viscosities but differing molecular weights and M/G ratios and to examine the effect on the mechanical
70 properties, sample volume conservation, working time, hardening time and deliverability of a hydrogel.
71 We **hypothesise** that the strength of the hydrogel will increase with increasing alginate concentration but
72 the sample size will reduce over time due to the increased cross-linking density. Although alginate is a
73 Non-Newtonian liquid that undergoes shear thinning, there will likely be a large increase in **viscosity** with
74 increasing alginate concentration and this will affect the deliverability of the hydrogel. In addition, the
75 effect of a **reduction** in molecular weight by sterilisation on the most suitable alginate is subsequently
76 examined. Gamma irradiation is known to greatly reduce the molecular weight of alginate and will likely
77 cause a significant reduction in the **hydrogel's** strength. This will also reduce the viscosity which may
78 help with the deliverability of the hydrogel. Gamma irradiation will be chosen as a possible sterilisation
79 technique for future work, provided there is a positive outcome of these results. This optimisation is
80 designed to improve the novel **hydrogel's** performance for the treatment of cerebral aneurysms.

81 **2. Material and Methods**

82 **2.1. Materials**

83 **2.1.1. Alginate Purification**

84
85
86 All reagents used were purchased from Sigma-Aldrich (Wicklow, Ireland), unless stated otherwise. Two
87 different techniques were used to produce the two different potassium alginates; a medium viscosity high-
88 G content alginate (MVG) and a medium viscosity high-M content alginate (MVM). The hydrogel was
89 purified from a sodium salt and alginate to a potassium alginate to reduce the endotoxin levels found in
90 the supplied alginate (Dusseault et al., 2006). All acid/base solutions were made up in 20 mmol/L of NaCl
91 in deionised water (DI), unless stated otherwise.

92 MVG was produced by dissolving 8g of a sodium salt from brown algae in 400 mL of DI. The alginate
93 pH was raised to 7.0 by adding a 0.5 M potassium hydroxide (KOH). The alginate was then precipitated
94 by adding 200 mL of methanol per 100 mL of alginate. The alginate was **filtered** through a 500 µm sieve
95 after 10 minutes. The alginate was then freeze-dried.

96 MVM was produced by dissolving 9 g of sodium alginate was dissolved in 900 mL of 1 mmol/L sodium
97 EGTA. The solution was then filtered through 11 µm and 2.5 µm filter paper respectively. The alginate
98 was then precipitated on ice by reducing the pH to 1.5 using a 2 M hydrochloric acid (HCl). The alginate
99 was decanted through a 500 µm stainless sieve and stirred 30 minutes in 200 mL of a 0.01 M HCl
100 solution and decanted again. This stirring and decanting was repeated three times. To remove proteins the
101 alginate was stirred for 30 minutes in 100 mL of a 0.01 M HCl solution with 20 mL of chloroform and 5
102 mL of 1-butanol, and collected in a 500 µm stainless steel sieve. This washing and collecting was
103 repeated three times. 350 mL of DI was added and the pH was raised to 7.0 by adding a 0.5 M KOH. The
104 alginate was stirred in a solution of 20 mL chloroform and 5 mL of 1-butanol per 100 mL of alginate and
105 centrifuged at a rate of 5,000 rpm for 5 minutes. The alginate was then separated using a pipette from the
106 chloroform/1-butanol solution. This washing and centrifuging was repeated once. Finally, the alginate
107 was precipitated by adding 200 mL of ethanol per 100 mL of alginate and filtered after 10 minutes. The
108 alginate was then freeze-dried.

109 A sample of the porous freeze-dried solid MVM alginate was gamma irradiated at Synergy Healthcare
110 (Westport, Ireland) by exposing the sample to a cobalt 60 source until a final irradiation dose of 25kGy
111 was achieved.

112 The required amount of freeze-dried alginate, to make the required alginate concentration, was then added
113 to 12 mL of DI.

114 2.1.2. Glass

115 The glass had a mole fraction composition of $0.33\text{SiO}_2 \cdot 0.18\text{Ga}_2\text{O}_3 \cdot 0.23\text{CaO} \cdot 0.11\text{P}_2\text{O}_5 \cdot 0.15\text{CaCl}_2$. A glass
116 frit of this composition was produced by melting the appropriate raw materials in a platinum 10%
117 rhodium crucible at 1480 °C for 1 hour. The molten mixture was then shock quenched into water. A glass
118 powder was then produced by grinding 30 g of glass frit using 15 mm diameter zirconia balls in a ball
119 mill (Pulverisette 6 classic Mono planetary ball mill, Fritsch GmbH, Germany) at 500 rpm for 10
120 minutes. Particles over 500 µm were removed by sieving the glass powder through a 500 µm sieve. 7.5 g
121 of the <500 µm particles were ground in 22.5 mL of DI using 5 mm zirconia balls in a ball mill at 500
122 rpm for 10 minutes. The glass mixture was dried in the oven at 130 °C.

123 2.1.3. Glucono-Delta-Lactone

124 D-(+)-Gluconic acid δ-lactone was purchased from Sigma Aldrich. The GDL particle size was reduced by
125 grinding 30 g at 500 rpm for 5 minutes using a ball mill. Particle size analysis is shown in Figure S 2.

126 2.1.4. Hydrogel preparation

127 The required amount of freeze-dried alginate was dissolved in 1.2 mL of DI. The novel hydrogel was
128 produced by mixing 4.6% of glass powder, 50 mg of GDL with the 1.2 mL of the alginate solution for 1

129 minute, unless otherwise stated. Design Expert 9 (Stat-Ease, Minneapolis, USA) was used to determine
130 the four alginate concentrations to be tested; 0.5%, 2.5%, 4.5% and 6.0%.

131 2.2. Methods

132 2.2.1. Alginate Characterisation

133 Gel permeation chromatography (GPC) and nuclear magnetic resonance spectroscopy (^1H NMR) were
134 carried out as follows in order to characterise the alginates produced.

136 GPC was carried out using a liquid chromatography system (Agilent 1200, Agilent, USA) equipped with
137 a Suprema Linear GPC column (PSS, Germany). The mobile phase used consisted of 0.1 M disodium
138 hydrogen phosphate containing 0.5 g/L of sodium nitrate buffered to pH 9. All samples were injected at a
139 concentration of 1 mg/mL, at a flow rate of 0.5 mL/min. Pullulan standards were used to construct the
140 calibration curves as alginate standards are not available. This is not an ideal standard as it can
141 overestimate the molecular weight (Andersen, Strand, Formo, Alsberg, & Christensen, 2012). However,
142 they are commonly used in determining molecular weights of alginates with a refractive index detector
143 (Barbetta, Barigelli, & Dentini, 2009)(Ding, Zhou, Zeng, Wang, & Shi, 2017)(Aida, Yamagata,
144 Watanabe, & Smith, 2010).

145 ^1H NMR analysis of the potassium alginate was carried out using a modified version of the standard
146 ASTM F2259–03. The alginate solution was prepared by mixing the alginate to a 0.1% (w/v) in DI. HCl
147 was used to bring the alginate pH to 5.6 and the alginate solution was stored in a water bath at 100 °C for
148 1 hour. HCl was used to further adjust the pH of the alginate to 3.8. The solution was stored again in a
149 water bath at 100°C for 30 minutes. The pH was then raised to 7 using NaOH and the alginate was freeze
150 dried. The alginate was then dissolved in 5 mL of 99% D₂O and freeze dried overnight. 12 mg of alginate
151 was dissolved in 1 mL of D₂O and placed in a NMR tube. The NMR of the alginate was tested using a
152 Bruker Advance 400 (Bruker, Massachusetts, USA) at 80°C. 64 scans were carried out using a 2s
153 relaxation delay. The M-block, G-block and alternating block sequences content were then calculated as
154 per the equations in ASTM F2259-03 using the produced spectrum.

155 2.2.2. Viscosity

156 The viscosity of each alginate at varying concentrations was determined at 24°C using a SV-10 tuning
157 forks Vibro Viscometer (A&D Company, Japan) running a sine wave formation at a constant frequency
158 of 30Hz and amplitude of less than 1 mm. The viscometer measures up to 10,000 mPa.s.

160 2.2.3. Volume Conservation

161 To examine whether the 1.2 mL hydrogel volume was conserved over time, the samples volumes were
162 measured after storage in 20 mL of DI for 1, 3 and 7 days. The hydrogel was mixed and poured into a

163 cylindrical mould (10 mm diameter and 14 mm height). The hydrogel was left to set for 1 hour and
164 incubated in DI at 37°C for the required amount of time. After the required time the hydrogel was
165 removed from the DI and dimensions were measured using callipers. ‘Volume conservation’ was
166 calculated by calculating the change in volume compared to the original (pre-incubated) volume.

167 **2.2.4. Compression testing**

168 To examine the mechanical properties of the novel hydrogel, compression testing was carried after storing
169 the novel hydrogel for 7 days in DI. The compression testing samples were made as described above.
170 After the required amount of time the hydrogel sample was compressed using a mechanical testing
171 machine (Z005, Zwick Roell, Germany) equipped with a 5 kN load cell. A 0.005 N pre-load was applied.
172 The samples were compressed up to 70% strain at a crosshead speed of 2 mm/min.

173 **2.2.5. Working and Hardening Time**

174 The working and setting time of each alginate was determined using a modified version of ISO 9917. The
175 setting time was found by mixing the hydrogel and placing a circular indenter (diameter: 6 mm, weight:
176 20 g) on the sample every 60 seconds. The hydrogel was considered set when it held the indenter without
177 causing an indentation in the hydrogel.

178 The working time was determined by stirring the hydrogel every 1 minute until the hydrogel would not
179 return to its original shape.

180 The hardening time is defined as the difference between the setting time and working time of the
181 hydrogel.

182 **2.2.6. Deliverability**

183 The deliverability of each alginate was tested by injecting the hydrogel by hand at the varying alginate
184 concentrations through a 3F micro catheter, using a quick stop syringe.

185 The optimum hydrogel was then injected through a 2.7F micro-catheter into a silicone side wall
186 aneurysm, (neck size of 2.5 x 6 mm, model H+N-S-A-005, Elastrat, Switzerland). A pulsatile blood pump
187 (1423, Harvard Apparatus, Mass., USA) was used to pump a 36:64 water:glycerol solution through the
188 aneurysm and to provide physiologically correct blood pressure (140/80 mmHg) and flow rates (700 mL
189 l/min). The pressure was measured at the aneurysm inlet and outlet using pressure transducers (DTX Plus
190 Disposable Pressure Transducer, Argon) which was amplified using a bridge analogue input (NI9237,
191 National Instrument) and the pressure was monitored using LabView. A 5 mm diameter balloon (Trek,
192 Abbott) was inflated adjacent to the aneurysm neck, to facilitate placement.

193 **2.2.7. Statistical analysis**

194 Student T-tests ($p < 0.05$) and ANOVA with Bonferroni's post hoc test was carried out using IBM SPSS
 195 (IBM, Armonk, NY).

196 **3. Results**

197 **3.1. Effect of alginate molecular weight and chemical composition**

198 **3.1.1. Alginate Characterisation**

199 GPC was carried out to determine the molecular weight (MW) of each alginate and ^1H NMR spectra of
 200 the alginates were used to determine the guluronic acid (F_G), mannuronic acid (F_M) and alternating block
 201 (F_{GM}) fractions, which were calculated as per ASTM F2259 – 03.


202 Table 1 gives the calculated results of the alginates produced; see Figure S 3 and Figure S 4 for graphs.
 203 MVG produced a low molecular weight (60kDa) alginate with a high-G content. MVM produced a high
 204 molecular weight (700kDa) alginate with a high-M content.

205 *Table 1 Alginate chemical composition*

Sample	Molecular weight	F_G	F_M	M/G	F_{GG}	F_{MM}	F_{GM}	$\bar{N}_{G>1}$
MVG	60kDa	0.52	0.48	0.92	0.38	0.33	0.14	7.08
MVM	700kDa	0.37	0.63	1.7	0.18	0.45	0.18	3.59

206 **3.1.2. Volume Conservation**

207 The volume of the samples with a low alginate concentration reduced in size, see Figure 1. A 4.5%
 208 alginate concentration approximately maintains its size or slightly expands (<5%) whilst the samples at
 209 the 6.0% alginate concentration expanded after 7 days.



210 *Figure 1 Volume conservation after storage for 7 days in DI at 37°C (n=5)*


211 **3.1.3. Viscosity**

212 Both alginates have a similar viscosity at each concentration and the viscosity increases with increasing
 213 alginate concentration (Figure S 5). Both the alginates have viscosity greater than 10,000 mPa.s at the
 214 6.0% alginate concentration.

219
220
221

3.1.4. Compression testing

Both hydrogel compositions at each concentration far exceed the minimum compressive strength (22 kPa) required.



222
223
224


Figure 2 (a) Compressive stress up to 70% strain and (b) Incremental modulus (30 to 50% strain) of the alginates at the 4 concentrations after storage for 7 days in DI at 37°C

225
226
227
228
229
230
231

The strength of the hydrogel was observed to increase from 0.5% to 2.5% alginate concentration. This was expected to continue with increased alginate concentration, as observed elsewhere (Draget, Skjåk Bræk, & Smidsrød, 1994; C K Kuo & Ma, 2001; Becker, Kipke, & Brandon, 2001), however, this is not observed here. The decreased strength observed at 4.5% and 6.0% may be caused by shortage of cross-linking cations. As there is no increase in GDL or glass content there will be no increase in ion availability to cross-link with increasing number of chains provided by the increased alginate concentration.

232
233
234
235

Figure 3 shows that increasing the glass content increases the modulus and strength of the hydrogel at a 4.5% alginate concentration. Increasing the glass content from 4.6% to 9.2% more than doubles both the strength and modulus of the hydrogel, with no further increase being observed with further glass addition (13.8%). This may be increased further with an increase in GDL content.



236
237
238

Figure 3 (a) Compressive stress up to 70% strain and (b) Incremental modulus (30 to 50% strain) of 4.5% and 6.0% MVM alginate with 50 mg GDL and an increased glass content after storage for 1 day in DI at 37°C (n=5)

239

3.1.5. Working Time and Hardening Time

240 Figure 4 shows the working and hardening time of each composition. For both alginates only the 4.5%
 241 and 6.0% alginate concentrations are within the required working and hardening time. There is an
 242 approximately linear decrease in working time for the MVG and MVM alginate ($R^2 = 0.91$ and $R^2 = 0.94$,
 243 respectively) and hardening time for the MVM alginate ($R^2 = 0.93$) with increasing alginate
 244 concentration. As there is no significant difference between the 0.5% and 2.5% hardening time ($p < 0.05$),
 245 there is not a linear reduction for the MVG alginate.

246
 247




Figure 4 Alginate a) working and b) hardening time (n=5)

3.1.6. Deliverability

248 The alginate concentration of 0.5% (either MVG or MVM) gave insufficient viscosity (41-44mPas) to
 249 remain in the aneurysm when blood flow was applied. The 2.5% and 4.5% alginate concentration of both
 250 MVG and MVM alginates (<10,000 mPa.s) would inject through the micro-catheter easily, up to 20
 251 minutes after mixing. The MVG and MVM alginates at 6.0% alginate concentration (>10,000 mPa.s)
 252 would not inject through the micro-catheter, blocking it 2 minutes after mixing the hydrogel.
 253

254 As the 4.5% concentration of the MVM alginate had the correct strength, sufficient volume conservation,
 255 and correct working and hardening times it was selected to inject into the aneurysm model. With the
 256 balloon inflated and the flow pump on, the hydrogel was injected into the 10 mm aneurysm with a
 257 2.5x2.5 mm neck two minutes before the end of the working time (22 minutes after mixing). The
 258 hydrogel was fully injected by the working time and the balloon remained inflated for two minutes. The
 259 hydrogel stayed within the aneurysm and remained in the aneurysm with no perceptible erosion once the
 260 balloon was deflated for the time tested (30 minutes).

3.2. Effect of Gamma Irradiation

261 As previously stated, the MVM alginate was the more suitable of the two alginates examined for
 262 treatment of cerebral aneurysms and hence was selected for gamma irradiation. A sample of the alginate
 263


264 was gamma irradiated by Synergy Healthcare (Westport, Ireland) at 25kGy to examine the effects of a
265 change in molecular weight alone and for sterilisation purposes.

266 3.2.1. Alginate Characterisation

267 GPC and ¹H NMR showed that gamma irradiation causes a reduction in alginate molecular weight to
268 180kDa without a change to the alginate chemical composition (Table 1).

269 3.2.2. Volume Conservation

270 Figure 5 shows that, again, the lower irradiated alginate concentrations shrink in volume whilst the 6.0%
271 alginate concentration increases in volume over 7 days for both alginates. The 4.5% alginate
272 concentration has minimal expansion in volume.




273
274 *Figure 5 Volume conservation after storage for 7 days in DI at 37°C (n=5)*

275 3.2.3. Viscosity

276 The results show that gamma irradiation reduces alginate viscosity, with values ranging from 2.83 to
277 86.43 mPa.s. The viscosity increases by approximately 6.25 mPa.s for each 1% increase in alginate
278 concentration for the gamma irradiated alginate, see Figure S 8.

279 3.2.4. Compression testing


280 Reduction in molecular weight caused by gamma irradiation greatly affects the compressive stress and
281 incremental modulus of the hydrogel compared to the non-irradiated sample ($p > 0.05$). Although the
282 gamma irradiated alginate has a compressive strength that exceeds the limit discussed in the introduction
283 (22 kPa), the incremental modulus of the alginate decreases with increasing alginate concentration and at
284 each concentration has a decreased strength compared to the non-irradiated alginate, see Figure 6.
285



286
287 **Figure 6** (a) Compressive stress up to 70% strain and (b) Incremental modulus (30 to 50% strain) of irradiated and non-
288 irradiated alginate compositions after storage for 7 days in DI at 37°C

289 3.2.5. Working Time and Hardening Time

290 The reduction in molecular weight of the gamma irradiated alginate significantly increases the working
291 and hardening time ($p > 0.05$), see Figure 9. The working and hardening times decrease linearly with
292 increasing alginate concentration for both irradiated and non-irradiated samples, i.e. $R^2 = 0.91, 0.91$ and
293 $R^2 = 0.91, 0.92$, respectively. However, at each concentration test, the gamma irradiated alginate is not
294 within the time limits for its intended application.



296
297 **Figure 7** Hydrogel a) working and b) hardening time ($n=5$)

298 3.2.6. Deliverability

299 None of the gamma irradiated alginate concentrations had sufficient viscosity to remain in the aneurysm
300 when blood flow was applied, similar to that of the 0.5% alginate concentration of the non-irradiated
301 alginate.

302 4. Discussion

303 From the GPC and ^1H NMR results we can see that two different alginates were produced, a MVM with a
304 high molecular weight and a MVG with a low molecular weight. Though the molecular weight of the

305 MVG alginate is over ten times less than that of the MVM alginate, the viscosities are similar (Figure S
306 5). This is not typical but may be due to differences in M/G ratios and G-block length, with higher G
307 content and length alginates being typically stiffer and more viscous compared to alginates with a high-M
308 content (Smith & Miri, 2011)(Nedovic & Willaert, 2013)(Jothisaraswathi & Rengasamy, 2006)(Schmid,
309 Fariña, Rehm, & Sieber, 2016). It has been shown that varying the alginate purification method results in
310 alginates with significantly different viscosities. The varying alginates and purification methods used here
311 may have an additional effect on the viscosity of the alginate due to variances in residual salts and impurities
312 and the resulting pH of the alginate solution (Dusseault et al., 2006; K. Y. Lee & Mooney, 2012;
313 McHugh, 2003).

314 It is clear from the results that the cross linking density of the hydrogel is important to control the strength
315 and volume conservation. At the 0.5% alginate concentration there is likely a shortage of alginate chains
316 and an excess of cations. At a 4.5% and 6.0% alginate concentration there is a shortage of cross-linking
317 ions and, as a result, there are alginate chains that are not optimally cross-linked.

318 The sample volume conservation exhibits results similar to those described by Kuo *et al* (Catherine K
319 Kuo & Ma, 2008). At a 0.5% and 2.5% alginate concentration the samples shrink and the 4.5% and 6.0%
320 alginate concentration samples expand (Figure 1). This may be due to the hydrogel's cross-linking
321 density decreasing with increasing alginate concentration as a result of the glass content, and hence ion
322 content, remaining constant. The lower concentration alginates have an increased cross-linking density.
323 This increased cross-linking increases the elastic forces that can resist the swelling caused by water
324 molecules diffusing into the hydrogel. As the concentration increases the cross-linking density decreases
325 allowing water to diffuse through the hydrogel and swell. Neither significant shrinkage nor expansion is
326 desired, as shrinkage may contribute to aneurysm recurrence and excessive sample expansion may cause
327 aneurysm rupture. Samples produced from 4.5% alginate concentration exhibit minimal swelling, which
328 suggests that this alginate concentration provides a cross-linking density that provides a high strength
329 while conserving sample volume.

330 For both the MVG and MVM alginate the incremental modulus and compressive strength increase from
331 0.5% to 2.5% alginate concentration (Figure 2). The incremental modulus and compressive strength then
332 decreases with further increased alginate concentration ($\geq 2.5\%$). The decrease above 2.5% alginate was
333 unexpected and may be due to a shortage of cross-linking ions. This shortage of ions may reduce the
334 cross-linking density and result in an inhomogeneous hydrogel that is prone to fracture. To explore this
335 further, the glass content was increased. This increased the strength for the 4.5% and 6.0% alginate
336 concentration whereby the increase in cations provided a higher cross-linking density (Figure 3). For each
337 of the concentrations, the MVM alginate had the highest modulus and compressive strength for each

338 alginate concentration. Typically, the high-G alginate would have the higher strength (Draget et al.,
339 1994); however, the increased molecular weight of the MVM alginate may compensate for the lower G-
340 block content and provides increased entanglements.

341 Though the MVG alginate has the shortest working time, the MVM alginate has the shortest hardening
342 time at each alginate concentration (Figure 4). This indicates that the working time is governed mostly by
343 the chemical composition of the alginate with a high-G content providing a decreased working time. The
344 hardening time of the alginate is governed mainly by the molecular weight of the alginate with a high
345 molecular weight alginate having decreased hardening time. Increasing the alginate concentration of each
346 alginate provides an increased number of ionic cross-linking locations and increased likelihood of chain
347 entanglements, causing working and hardening time to reduce in each hydrogel.

348 The deliverability of the hydrogel can be determined from the viscosity, with ungelled alginates up to
349 9,000 mPa.s being injectable through a micro-catheter. For the intended applications of this hydrogel; the
350 strength, conservation of sample volume, working time and hardening time, along with the deliverability
351 of this hydrogel must be considered. The 4.5% concentration of the MVM alginate met each of the
352 requirements and was tested in an aneurysm model with physiological pressures. This hydrogel remained
353 in the aneurysm without migrating.

354 Gamma irradiation of the MVM alginate was shown to have no effect on the M/G ratio of the alginate.
355 However, it does cause scissions of the glycosidic bonds, which reduces the molecular weight of the
356 alginate.

357 As expected, viscosity was seen to decrease with gamma irradiation of the MVM alginate, as expected,
358 due to decreased chain entanglements (C K Kuo & Ma, 2001; Dusseault et al., 2006; Rendeovski &
359 Mahmudi, 2012; Ouwerx, Velings, Mestdagh, & Axelos, 1998)

360 From the alginate working and hardening time data it can be seen that the gamma irradiated alginate has
361 the longest working and hardening time due to the high-M content and low molecular weight having a
362 reduced number of ionic cross-linking locations (Popeski-Dimovski et al., 2012). Although usability of
363 the gamma irradiated alginate may be improved by increasing alginate concentration and optimising the
364 glass and GDL content, an alternative method of sterilization may be more efficient, such as sterilisation
365 by filtration in a sterile manufacturing environment.

366 A range of injectable polymer formulations have been developed for soft tissue applications but many
367 contain toxic monomers, activators and free radicals. The gelation rate of the hydrogel described here is

368 slow compared to other alginate hydrogels (Larsen, Bjørnstad, Pettersen, Tønnesen, & Melvik, 2015; Lee
369 et al., 2003), which allows the hydrogel to be delivered and set, within a clinically applicable time.

370 Though GDL can be used with alginate to produce acid gels, this is likely not the case with the current
371 hydrogel due to the high strengths and relatively rapid gelation rates observed. The addition of GDL
372 results in a reduced pH during setting, which may affect the hydrogel's biocompatibility. The pH of the
373 storage **medium** drops by 0.50 with the 4.5% high-M alginate. However, the presence of alkali ions in the
374 bioactive glass has a neutralizing effect over 24 hours. It should be noted that this temporary reduction in
375 pH, as occurs with many synthetic biomaterials, may result in an increased inflammatory and fibrotic
376 response *in vivo* (Edgar et al., 2016).

377 For an aneurysm filler to be effective it should have sufficient strength in order to behave similarly to
378 native cerebral tissue; diverting flow and **withstanding** haemodynamic stresses caused by arterial
379 expansion and contraction and blood flow forces (static, dynamic and shear). A low elastic modulus is
380 required to insure stress caused by blood flow is not transferred to the damaged tissue, causing aneurysm
381 rupture. A calcium alginate gel that was designed for embolization was reported to have a compressive
382 strength of 124kPa at 60% strain (Becker et al., 2001). Onyx[®], is a non-adhesive material approved for
383 the treatment of cerebral aneurysms in Europe, has been observed to have a maximum compressive
384 strength of 3 MPa (Ohyama, Ko, Miura, Iwata, & Taki, 2004). However, Onyx[®] sets rapidly when in
385 contact with blood, which combined with the slow injection rate, is not ideal for placement.

386 The optimised hydrogel in this study exhibits a compressive strength of 280 kPa. Although it is not equal
387 in strength to Onyx[®], it may act to support the existing tissue in its function, without transferring
388 excessive stress to the damaged tissue. The optimised hydrogel reported herein has higher incremental
389 modulus and compressive strength compared to those of other ionically cross-linked alginate hydrogels
390 described in the literature at similar alginate concentrations and chemical compositions (Becker et al.,
391 2001; C K Kuo & Ma, 2001). This novel material reported herein likely has a greater mechanical integrity
392 than the currently used coil technology that can compact with blood flow, which though not optimal,
393 continues to function in this mechanical environment (Gallas et al., 2009; Sluzewski et al., 2004).

394 Agglomerates were clearly visible in the hydrogel both during and after setting, which may affect
395 consistency of strength and setting, therefore, future testing will be carried out to minimise these
396 agglomerates. The adhesive nature of the hydrogel will also be examined as this is important to reduce
397 aneurysm recurrence. Further **optimisation of** the sterilisation techniques **for** each **hydrogel** component of
398 the hydrogel will also need prior to commercial application.

399 **5. Conclusion**

400 From the results it can be seen that alginate concentration, molecular weight and chemical composition
401 affect the sample volume conservation, viscosity, strength, deliverability, working and hardening time of
402 the novel hydrogels. An alginate with an increased molecular weight and high-M content provides a
403 hydrogel with an increased working time and decreased hardening time while providing the required
404 strength which is advantageous for a cerebral aneurysm filler. Alginates with a viscosity between 2,000
405 mPa.s and 9,000 mPa.s can be injected through a micro catheter while providing sufficient viscosity to
406 remain within an aneurysm without migration.

407 Sterilisation by gamma irradiation causes a reduction of molecular weight which decreases the alginate's
408 viscosity and strength and increases the hydrogel's working and hardening time. This is undesirable for
409 the treatment of cerebral aneurysms. For this application, an alternative, less aggressive method of
410 sterilisation will be required.

411 **Acknowledgements**

412 This work was supported by Enterprise Ireland Commercialization Fund through the grant CF/2013/3364.

413 **References**

414 Aida, T. M., Yamagata, T., Watanabe, M., & Smith, R. L. (2010). Depolymerization of sodium alginate
415 under hydrothermal conditions. *Carbohydrate Polymers*, 80(1), 296–302.
416 <http://doi.org/10.1016/j.carbpol.2009.11.032>

417 Andersen, T., Strand, B. L., Formo, K., Alsberg, E., & Christensen, B. E. (2012). Chapter 9 Alginates as
418 biomaterials in tissue engineering. In *Carbohydrate Chemistry: Volume 37* (Vol. 37, pp. 227–258).
419 The Royal Society of Chemistry. <http://doi.org/10.1039/9781849732765-00227>

420 Barbetta, A., Barigelli, E., & Dentini, M. (2009). Porous Alginate Hydrogels: Synthetic Methods for
421 Tailoring the Porous Texture. *Biomacromolecules*, 10(8), 2328–2337.
422 <http://doi.org/10.1021/bm900517q>

423 Becker, T. A., Kipke, D. R., & Brandon, T. (2001). Calcium alginate gel: A biocompatible and
424 mechanically stable polymer for endovascular embolization. *Journal of Biomedical Materials*
425 *Research*, 54(1), 76–86. [http://doi.org/10.1002/1097-4636\(200101\)54:1<76::AID-JBM9>3.0.CO;2-](http://doi.org/10.1002/1097-4636(200101)54:1<76::AID-JBM9>3.0.CO;2-V)
426 V

427 Brisman, J. L., Song, J. K., & Newell, D. W. (2006). Cerebral Aneurysms. *New England Journal of*
428 *Medicine*, 355(9), 928–939. <http://doi.org/10.1056/NEJMra052760>

429 Cipolla MJ. (2009). Control of Cerebral Blood Flow. In *The Cerebral Circulation*. San Rafael (CA):

430 Morgan & Claypool Life Sciences.

431 Clarkin, O. (2017). Biomaterial Research Group. Retrieved from www.biomaterials.ie

432 Crobeddu, E., Lanzino, G., Kallmes, D. F., & Cloft, H. J. (2012). Review of 2 Decades of Aneurysm-
433 Recurrence Literature, Part 2: Managing Recurrence after Endovascular Coiling. *American Journal*
434 *of Neuroradiology* . <http://doi.org/10.3174/ajnr.A2958>

435 Ding, W., Zhou, J., Zeng, Y., Wang, Y., & Shi, B. (2017). Preparation of oxidized sodium alginate with
436 different molecular weights and its application for crosslinking collagen fiber. *Carbohydrate*
437 *Polymers*, 157, 1650–1656. <http://doi.org/10.1016/j.carbpol.2016.11.045>

438 Draget, K. I., Skjåk Bræk, G., & Smidsrød, O. (1994). Alginic acid gels: the effect of alginate chemical
439 composition and molecular weight. *Carbohydrate Polymers*, 25(1), 31–38.
440 [http://doi.org/10.1016/0144-8617\(94\)90159-7](http://doi.org/10.1016/0144-8617(94)90159-7)

441 Dusseault, J., Tam, S. K., Menard, M., Polizu, S., Jourdan, G., Yahia, L., & Halle, J.-P. (2006).
442 Evaluation of alginate purification methods: effect on polyphenol, endotoxin, and protein
443 contamination. *Journal of Biomedical Materials Research. Part A*, 76(2), 243–251.
444 <http://doi.org/10.1002/jbm.a.30541>

445 Edgar, L., McNamara, K., Wong, T., Tamburrini, R., Katari, R., & Orlando, G. (2016). Heterogeneity of
446 Scaffold Biomaterials in Tissue Engineering. *Materials*, 9(5).

447 Gallas, S., Januel, A. C., Pasco, A., Drouineau, J., Gabrillargues, J., Gaston, A., ... Herbreteau, D. (2009).
448 Long-term follow-up of 1036 cerebral aneurysms treated by bare coils: a multicentric cohort treated
449 between 1998 and 2003. *AJNR. American Journal of Neuroradiology*, 30(10), 1986–1992.
450 <http://doi.org/10.3174/ajnr.A1744>

451 Jothisarawathi, S., & Rengasamy, B. B. R. (2006). Seasonal studies on alginate and its composition II:
452 *Turbinaria conoides* (J.Ag.) Kütz. (Fucales, Phaeophyceae). *J Appl Phycol*. <http://doi.org/DOI>
453 [10.1007/s10811-006-9089-8](http://doi.org/10.1007/s10811-006-9089-8)

454 Kim Nelson, P., & Levy, D. I. (2001). Balloon-assisted Coil Embolization of Wide-necked Aneurysms of
455 the Internal Carotid Artery: Medium-term Angiographic and Clinical Follow-up in 22 Patients.
456 *American Journal of Neuroradiology* , 22(1), 19–26. Retrieved from
457 <http://www.ajnr.org/content/22/1/19.abstract>

458 Kuo, C. K., & Ma, P. X. (2001). Ionically crosslinked alginate hydrogels as scaffolds for tissue
459 engineering: Part 1. Structure, gelation rate and mechanical properties. *Biomaterials*, 22.

460 [http://doi.org/10.1016/S0142-9612\(00\)00201-5](http://doi.org/10.1016/S0142-9612(00)00201-5)

461 Kuo, C. K., & Ma, P. X. (2008). Maintaining dimensions and mechanical properties of ionically
462 crosslinked alginate hydrogel scaffolds in vitro. *Journal of Biomedical Materials Research Part A*,
463 84A(4), 899–907. <http://doi.org/10.1002/jbm.a.31375>

464 Larsen, B. E., Bjørnstad, J., Pettersen, E. O., Tønnesen, H. H., & Melvik, J. E. (2015). Rheological
465 characterization of an injectable alginate gel system. *BMC Biotechnology*, 15(1), 1–12.
466 <http://doi.org/10.1186/s12896-015-0147-7>

467 Lee, D. W., Choi, W. S., Byun, M. W., Park, H. J., Yu, Y.-M., & Lee, C. M. (2003). Effect of gamma-
468 irradiation on degradation of alginate. *Journal of Agricultural and Food Chemistry*, 51(16), 4819–
469 4823. <http://doi.org/10.1021/jf021053y>

470 Lee, K. Y., & Mooney, D. J. (2012). Alginate: properties and biomedical applications. *Progress in*
471 *Polymer Science*, 37(1), 106–126. <http://doi.org/10.1016/j.progpolymsci.2011.06.003>

472 McHugh, D. J. (2003). Alginate. In *A guide to the seaweed industry* (pp. 39–50). Food and Agriculture
473 Organization of the United Nations.

474 Morais, D. S., Rodrigues, M. A., Silva, T. I., Lopes, M. A., Santos, M., Santos, J. D., & Botelho, C. M.
475 (2013). Development and characterization of novel alginate-based hydrogels as vehicles for bone
476 substitutes. *Carbohydrate Polymers*, 95(1), 134–42. <http://doi.org/10.1016/j.carbpol.2013.02.067>

477 Munarin, F., Bozzini, S., Visai, L., Tanzi, M. C., & Petrini, P. (2013). Sterilization treatments on
478 polysaccharides: Effects and side effects on pectin. *Food Hydrocolloids*, 31(1), 74–84.
479 <http://doi.org/10.1016/j.foodhyd.2012.09.017>

480 Nedovic, V., & Willaert, R. (2013). Alginate as a Carrier for Cell Immobilisation. In *Fundamentals of*
481 *Cell Immobilisation Biotechnology* (pp. 33–53). Springer Netherlands. Retrieved from
482 <https://books.google.ie/books?id=ts7tCAAQBAJ>

483 Ohyama, T., Ko, I. K., Miura, A., Iwata, H., & Taki, W. (2004). ProNectin F-grafted-ethylene vinyl
484 alcohol copolymer (EVAL) as a liquid type material for treating cerebral aneurysm--an in vivo and
485 in vitro study. *Biomaterials*, 25(17), 3845–52. <http://doi.org/10.1016/j.biomaterials.2003.10.021>

486 Ouwerx, C., Velings, N., Mestdagh, M. ., & Axelos, M. A. . (1998). Physico-chemical properties and
487 rheology of alginate gel beads formed with various divalent cations. *Polymer Gels and Networks*,
488 6(5), 393–408. [http://doi.org/10.1016/S0966-7822\(98\)00035-5](http://doi.org/10.1016/S0966-7822(98)00035-5)

489 Popeski-Dimovski, R., Rendeovski, S., & Mahmudi, N. (2012). Change in Gellation Time of Sodium
490 Alginate Biopolymer Hydrogels With Change of Dose of Gamma Irradiation. *Physica Macedonica*
491 *61*, 67–72.

492 Schmid, J., Fariña, J., Rehm, B., & Sieber, V. (2016). Alginate-modifying enzymes: biological roles and
493 biotechnological uses. In *Microbial Exopolysaccharides: From Genes to Applications*: (pp. 70–79).
494 Retrieved from <https://books.google.ie/books?id=EJFADgAAQBAJ>


495 Sluzewski, M., van Rooij, W. J., Slob, M. J., Bescós, J. O., Slump, C. H., & Wijnalda, D. (2004).
496 Relation between Aneurysm Volume, Packing, and Compaction in 145 Cerebral Aneurysms Treated
497 with Coils. *Radiology*, *231*(3), 653–658. <http://doi.org/10.1148/radiol.2313030460>

498 Smith, A. M., & Miri, T. (2011). Alginates in Foods. In *Practical Food Rheology* (pp. 113–132). Wiley-
499 Blackwell. <http://doi.org/10.1002/9781444391060.ch6>

500

501

502 **Supplementary Material**




503

504

Figure S 1 Schematic of novel hydrogel being injected into a cerebral aneurysm (Clarkin, 2017)

505



506

507

Figure S 2 Particle Size Analysis of glass purchased from sigma before and after grinding


508

Effect of alginate molecular weight and chemical composition

509

Alginate Characterisation


510




511

512

Figure S 3¹H NMR of MVG and MVM alginate




513
514 *Figure S 4 GPC of MVG and MVM alginate*



515
516 *Figure S 5 Viscosity of the alginates at each of the four concentrations (n=5)*

517 **Effect of Gamma Irradiation**


518 **Alginate Characterisation**



519
520 *Figure S 6 ¹H NMR of gamma irradiated and non-irradiated alginate*

521 The GPC, Figure S 7, shows that gamma irradiation causes scissions of the glycosidic bonds, reducing the
522 molecular weight of the alginate.

523



524
525 **Figure S 7** GPC of gamma irradiated and non-irradiated alginate


526 Using Equation S1 it was calculated that gamma irradiation causes approximately 3.3 chain breaks per
527 molecule.

528

$$529 \quad N = \frac{M_0}{M} - 1$$

530 *Equation S 1* Calculating chain breaks per molecule

531 Where M_0 is the original molecular weight and M is the molecular weight of the alginate following
532 irradiation (D. W. Lee et al., 2003).



534
535 **Figure S 8** Viscosity of alginates at each of the four concentrations ($n=5$)

536